A new monacolin analogue from Xuezhikang capsule.

Abstract

Xuezhikang capsule (ethanol extract of red yeast rice) which produced by Beijing WBL Peking University Biotech Co., Ltd., is a traditional Chinese medication with 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibiting activity. Clinical trials indicated that Xuezhikang with lipid-lowering action could reduce the risk of cardiac events and total mortality of Chinese coronary heart disease patients. To exactly explain the clinical features of Xuezhikang, we undertook a complete study of the chemical constituents of Xuezhikang. This study resulted in the isolation of a new monacolin analogue, named alpha, beta-dehydromonacolin L (1), along with two known compounds: monacolin L (2) and 3-(2, 6-dimethyl-1, 2, 4a, 5, 6, 7, 8, 8a-octahydronaphthalen-1-yl)propanoic acid (3). The chemical structures were determined by extensive 1D and 2D NMR and MS spectroscopic analysis.

• Authors: Xue-mei Li, Xing-hai Shen, Zhen-wen Duan, Shu-ren Guo
• Journal: Yao xue xue bao = Acta pharmaceutica Sinica (Yao Xue Xue Bao) Vol. 46 Issue 5 Pg. 564-7 (May 2011) ISSN: 0513-4870 [Print] China
• PMID: 21800545 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• 3-(2,6-dimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)propanoic acid
• Drugs, Chinese Herbal
• Naphthalenes
• Propionates
• alpha,beta-dehydromonacolin L
• xuezhikang
• monacolin L

Topics

• Drugs, Chinese Herbal (chemistry)
• Molecular Structure
• Naphthalenes (chemistry, isolation & purification)
• Propionates (chemistry, isolation & purification)